Gerresheimer AG
XETRA:GXI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gerresheimer AG
Other Equity
Gerresheimer AG
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Gerresheimer AG
XETRA:GXI
|
Other Equity
-€145.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-10%
|
|
|
E
|
Evotec SE
XETRA:EVT
|
Other Equity
-€34m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
Other Equity
€246.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Gerresheimer AG
Glance View
Gerresheimer AG, nestled in the heart of Germany, has evolved into a cornerstone of the pharmaceutical and healthcare industries. Its beginnings were humble, rooted in glass manufacturing over a century ago, but the company has since metamorphosed into a leading provider of specialized products for the global healthcare market. Today, Gerresheimer's portfolio stretches well beyond glass, encompassing a range of highly technical and innovative products. The company specializes in producing glass and plastic containers, including vials, ampoules, and cartridges, which are crucial for delivering drugs and vaccines safely to patients worldwide. Its sophisticated offerings extend to complex drug delivery devices like insulin pens and inhalers, showcasing its deep integration into the supply chains of major pharmaceutical companies. Gerresheimer's business model thrives on close partnerships with these pharmaceutical giants, crafting tailor-made solutions for diverse therapeutic areas. This strategic alignment positions it well amid growing global health needs and an aging population, driving steady demand for its high-margin products. Its operations are bolstered by an international footprint of production facilities, allowing for high-quality, efficient manufacturing and distribution. This network not only enhances its logistics but also supports the company's commitment to innovation, enabling it to meet specific regulatory and market requirements across different regions. Ultimately, Gerresheimer AG makes its mark and profits through a combination of cutting-edge technology, stringent quality standards, and strategic relationships, securing its place as a vital player in the global healthcare ecosystem.
See Also
What is Gerresheimer AG's Other Equity?
Other Equity
-145.4m
EUR
Based on the financial report for Aug 31, 2025, Gerresheimer AG's Other Equity amounts to -145.4m EUR.
What is Gerresheimer AG's Other Equity growth rate?
Other Equity CAGR 10Y
-10%
Over the last year, the Other Equity growth was -59%.